Dosing & Uses
Dosage Forms & Strengths
capsule
- 0.5mcg
- 2.5mcg
injectable solution
- 4mcg/2mL multidose 2-mL vial
- 10mcg/5mL multidose 5-mL vial
Dialysis
Initial dose
- 10 mcg PO 3 times/week at end of dialysis, may increase by 2.5 mcg/dose, no more than 20 mcg/dose 3 times/week OR
- 4 mcg IV bolus 3 times/week following dialysis, may increase by 1-2 mcg/dose q8Weeks
Dose Modifications
- If intact parathyroid hormone (iPTH) <100 pg/mL, withhold for 1 week; then reinitiate at reduced dose of at least 2.5 mcg PO lower than last dose or at least 1 mcg IV lower than last dose
- Reduce dose or stop the drug if calcium and phosphorus are persistently above normal range; if interrupted, reinitiate at lower doses as above
- Monitor: Serum calcium and phosphorus, iPTH
Pre-dialysis
Initial: 1 mcg PO qDay, may increase by 0.5 mcg/dose q2Weeks
Reduce or interrupt dose if iPTH concentration falls or calcium and phosphorus are persistently above normal range (consult package insert); reinitiate at least 0.5 mcg lower than last dose
Renal Impairment
Dose adjustment not necessary
Hepatic Impairment
Caution; guidelines not available
Other Indications & Uses
Secondary hyperparathyroidism associated with chronic kidney disease
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
Frequency Not Defined
Edema
Palpitation
Chills
Dizziness
Headache
Malaise
Nausea
Vomiting
Hypercalcemia
Hypercalciuria
Anorexia
Constipation
Dyspepsia
Arthralgia
Edema
Weight increase
Sleep disorder
Dyspnea Pruritus
Postmarketing Reports
Hypersensitivity reactions (patients on hemodialysis)
Warnings
Contraindications
Hypersensitivity
Hypercalcemia, hyperphosphatemia, hypervitaminosis D
Cautions
Monitor serum calcium and phosphorus frequently; reduce dose or stop the drug if Ca x P product >75 mg²/dL²
Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate action of digitalis drugs; chronic hypercalcemia can lead to generalized vascular calcification and other soft-tissue calcification; in chronic kidney disease maintain Ca x P product at <55 mg²/dL²
Use with caution in patients receiving digitalis; digitalis toxicity is potentiated by hypercalcemia
Decrease dose if hypercalcemia or hyperphosphatemia occurs
Serious hypersensitivity reactions, including fatal outcome, in patients on hemodialysis, reported post marketing; hypersensitivity reactions include anaphylaxis with symptoms of angioedema (involving face, lips, tongue and airways), hypotension, unresponsiveness, chest discomfort, shortness of breath, and cardiopulmonary arrest; reactions may occur separately or together
Use oral calcium-based or other non-aluminum-containing phosphate binders and a low phosphate diet to control serum phosphorus levels in patients undergoing dialysis
Pregnancy & Lactation
Pregnancy
Limited available data in pregnant women are insufficient to identify drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes; there are risks to mother and fetus associated with chronic kidney disease in pregnancy as it increases risk for maternal hypertension and preeclampsia, miscarriage, preterm delivery polyhydramnios, stillbirth, and low-birth-weight infants
Animal data
- In reproduction studies in rats and rabbits treated during organogenesis at up to 20 mcg/kg/day and 0.1 mcg/kg/day, respectively (approximately 25 times (rats) and less than (rabbits) maximum recommended human oral dose of 60 mcg/week based on mcg/m2 body surface area), no adverse developmental effects observed
Lactation
There is no information available on presence of doxercalciferol in human milk, effects of drug on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from drug or from underlying maternal condition
Infants exposed to drug through breast milk should be monitored for signs and symptoms of hypercalcemia, including seizures, vomiting, constipation and weight loss; consider monitoring of serum calcium in infant
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Doxercalciferol is metabolized to the active form of vitamin D, which in turn controls the reabsorption of calcium by the kidneys, controls the intestinal absorption of dietary calcium, and along with parathyroid hormone controls the mobilization of calcium from the skeleton.
Absorption
Onset: IV: 10-12 wk, PO: 3-4 months
Peak Plasma Time: 8-12 hr
Metabolism
Metabolism: in liver to hepatic vitamin D 25-hydroxylases to 1,25-dihydroxyvitamin D2 (active)
Metabolites: 1,25-dihydroxyvitamin D2 (active), responsible for most of metabolic effects of doxercalciferol and 1,24-dihydroxyvitamin D2 (minor metabolite)
Elimination
Half-Life: 32-37 hr (active metabolite 1,25-dihydroxyvitamin D2)
Dialyzable: No (HD)
Administration
IV Administration
Administer by IV bolus at end of dialysis session
Storage
Capsule: 15-30ºC (59-86ºF)
Unopened vial: 15-30ºC (59-86ºF)
Opened multiple-dose vial: May store up to 3 days at 2-8ºC (36-46ºF); discard unused portion in vial after 3 days
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
doxercalciferol oral - | 1 mcg capsule | ![]() | |
doxercalciferol oral - | 0.5 mcg capsule | ![]() | |
doxercalciferol oral - | 2.5 mcg capsule | ![]() | |
Hectorol intravenous - | 4 mcg/2 mL vial | ![]() | |
Hectorol intravenous - | 4 mcg/2 mL vial | ![]() | |
Hectorol intravenous - | 2 mcg/mL vial | ![]() | |
doxercalciferol intravenous - | 4 mcg/2 mL vial | ![]() | |
doxercalciferol intravenous - | 4 mcg/2 mL vial | ![]() | |
doxercalciferol intravenous - | 4 mcg/2 mL vial | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.